Results 161 to 170 of about 17,592 (206)

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. [PDF]

Breast
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS.   +9 more
europepmc   +1 more source

HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells. [PDF]

Proc Natl Acad Sci U S A
Cottrell O, Rowntree A, Chopra K, Mackellar E, Noble B, Dixon HL, Healy C, Clarke RB, Papalopulu N.   +8 more
europepmc   +1 more source

Osteosarcoma 3D patient derived cultures to test genome-informed personalized treatment options: a feasibility study. [PDF]

Front Med (Lausanne)
Palubeckaitė I, Venneker S, Franceschini N, Wijers-Koster P, Agaser C, Briaire-de Bruijn I, Kruisselbrink AB, van den Akker B, Mei H, Cleton-Jansen AM, Gelderblom H, van de Sande MAJ, Bovée JVMG.   +12 more
europepmc   +1 more source

CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver. [PDF]

Mol Cancer
Jin B, Yang L, Peng W, Luo Z, Wei D, Zhang J, Zhao L, Zhong J, Ye Q, Li P, Zhang P, Liang L, Pan J.   +12 more
europepmc   +1 more source

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors. [PDF]

Sci Rep
Torrisi R, Giordano L, Pancetti S, Carnaghi C, Basilico V, Palumbo R, Gerosa R, Saltalamacchia G, Sanò MV, Santoro A, Fernandes B.   +10 more
europepmc   +1 more source

The dynamics of centromere assembly and disassembly during quiescence. [PDF]

J Cell Biol
Marescal O, Su KC, Moodie B, Taylor NJL, Cheeseman IM.   +4 more
europepmc   +1 more source

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. [PDF]

Curr Oncol
Seyyar M, Kalem A, Sali M, Karabuğa B, Sahin TK, Dişli AK, Türkel A, Karadurmuş B, Şahin Hafızoğlu E, Avcı N, Bilgetekin I, Köse Baytemur N, Uguztemur E, Oflazoğlu U, Gür HB, Hacıbekiroğlu İ, Akkuş AF, Topaloğlu S, Bayramgil A, Dülgar Kaya Ö, Yazıcı M, Şakalar T, Akay S, Majidova N, Guliyev M, Alan Ö, Gülcü S, Eren T, İmamoğlu Gİ, Güren AK, Köstek O, Ünlü A, Ozturk B, Aydın E, Safarov S, Doğan B, Tükenmez MA, Demir T, Şahin E, Erdemoğlu E, Keskin Uzundere F, Bütün O, Karabulut B, Uzun M, Baydaş T, Karaman E, Arak H, Ekinci F, Aykan MB, Ertürk İ, Guven DC, Deligönül A, Karaçin C, Ateş Ö, İnanç M, Yeşil H, Aksoy S, Köşeci T, Ökten İN, Yıldırım HÇ, Çabuk D.   +60 more
europepmc   +1 more source

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. [PDF]

Curr Oncol
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S.   +10 more
europepmc   +1 more source

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data. [PDF]

Breast Cancer Res
Veta Darkovski J, Michelon I, Gazzoni G, Mamede I, Jeong Y, Cavalcante L.   +5 more
europepmc   +1 more source

CDK4/6 Inhibitors for Breast Cancer Therapy-A Review of Clinical Trials, Structural and Computational Approaches. [PDF]

Pharmaceuticals (Basel)
Avdičević A, Lešnik S, Bren U, Čavka L.   +3 more
europepmc   +1 more source